Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Novartis Awaits Invite To Bid On Aventis, Says Combination Is "Viable"

This article was originally published in The Pink Sheet Daily

Executive Summary

Novartis wants a formal invitation from the Aventis board and a "neutral position" by the French government before it enters into merger negotiations. Novartis believes there is a "business case" for the merger, which it envisions as a two-step transaction including a spin-off of "non-core" products.

You may also be interested in...



Sanofi Holds Line On Aventis Merger Price; Novartis Enters Talks

Sanofi will continue to evaluate the market reaction before deciding whether to sweeten its bid. Novartis accepts Aventis’ invitation to explore a deal; the move indicates France has expressed neutrality on an Aventis/Novartis combination.

Sanofi Holds Line On Aventis Merger Price; Novartis Enters Talks

Sanofi will continue to evaluate the market reaction before deciding whether to sweeten its bid. Novartis accepts Aventis’ invitation to explore a deal; the move indicates France has expressed neutrality on an Aventis/Novartis combination.

Aventis Sues To Block Sanofi Bid; Warns That “Synergies” Would Hit Hard In U.S.

New Jersey lawsuit notes that Sanofi projects significant savings from merger but is downplaying impact in France and Germany. Aventis continues no-holds-barred defense against Sanofi bid.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS058927

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel